Home World News Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2... World News Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements By Ogkologos - June 11, 2026 244 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FIGHT-302 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Scanxiety September 15, 2021 Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS... February 22, 2023 Flame of Hope Awards: Celebrating our volunteers April 3, 2023 New lung cancer treatment combo approved on NHS in England January 12, 2022 Load more HOT NEWS 41-Year-Old Wrinkled Woman Who Ages 8 Times Faster Than Normal Is... Two-Time Breast Cancer Warrior Left Devastated After Package Full of Meds... FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma This Common Antibiotic May Help Support Immune System in Cancer Patients...
